May 26, 2010 – The 12-month study results for a drug-eluting stent that uses hundreds of tiny holes, filled with bioresorbable drug polymer to reduce tissue/polymer contact, demonstrated excellent safety and efficacy outcomes. The results from the NEVO RES-I clinical trial were presented yesterday at EuroPCR in Paris.
The Nevo sirolimus-eluting coronary stent is being compared to the Taxus Liberte paclitaxel-eluting coronary stent. Through 12-month follow-up, there have been no episodes of stent thrombosis reported in the Nevo arm, whereas two such events have been reported in patients treated with the Taxus Liberte, and a third event in this arm was reported after 13 months. Additionally there have been no cases of cardiac death or out-of-hospital myocardial infarction (MI) for patients receiving Nevo.
While the trial was not powered for clinical endpoints and thus no statistically-significant differences were observed, the rates of death, MI, the need for repeat revascularization, and the occurrence of stent thrombosis numerically favored Nevo to an even greater degree at 12 months. Similar trends were observed in the predefined subgroups of patients with diabetes and patients with lesion lengths less than or greater than 20 mm.
Restenosis Rates
At the six-month primary endpoint of this prospective, randomized clinical trial, Nevo was reported to be superior to Taxus Liberte in in-stent late lumen loss, which is tissue growth within a stent. Specifically, in-stent late lumen loss was reduced by 64 percent in the Nevo arm as compared to the Taxus Liberte arm (0.13 mm compared to 0.36 mm, p
“These data suggest we may be looking at a significant advance in treatment options for coronary disease that allows precise stent-based delivery of drug and is capable of reducing long-term safety complications," said Alexandre Abizaid, M.D., the chief of coronary interventions at the Institute Dante Pazzanese of Cardiology, Sao Paulo, Brazil. He is also a visiting professor of medicine at Columbia University, New York. "Since stent thrombosis and the drugs required to protect against it are such significant clinical issues, it is particularly pleasing to see the excellent safety outcomes associated with Nevo maintained over 12 months. These results also suggest the need for further study of whether abbreviating or interrupting antiplatelet therapy with this treatment would result in fewer adverse events than would currently be expected in drug-eluting stent patients."
Nevo RES-I Study Overview
The Nevo RES-I study was a randomized, multicenter comparison of Nevo to the Taxus Liberte stent in de novo, native coronary artery lesions. The study involved 394 patients at 40 sites throughout Europe, South America, Australia and New Zealand. Patients underwent angiographic follow-up at six months, received clinical follow-up at 30 days and six and 12 months, and will be followed annually for the next five years. The primary endpoint was in-stent late loss at six months. Key secondary endpoints include target lesion failure, target vessel failure, MACE, stent thrombosis, target lesion revascularization, target vessel revascularization, and angiographic in-stent and in-segment binary restenosis at six months
.
The Nevo Stent
Nevo is the first sirolimus-eluting stent utilizing hundreds of small reservoirs in the stent struts that are filled with an absorbable drug-polymer matrix. This is designed to minimize polymer contact with the vessel wall at implant, and allow transformation from a drug eluting stent into a bare metal stent in as little as 90 days. Currently available drug-eluting stents have surfaces completely coated in drug and a permanent polymer. Cordis submitted Nevo for CE-marking in March 2010.
The stent is an investigational device and is not approved or available for sale in any market.
For more information: www.cordis.com
April 24, 2024 
